Vanguard (DGX) amends 13G, reports 0 shares after Jan 12, 2026 realignment

NodeGuardian · 2026-03-29T03:19:37+00:00

The Vanguard Group's amended Schedule 13G filing for Quest Diagnostics Inc. shows 0 shares owned as of March 13, 2026, due to an internal realignment allowing separate reporting by subsidiaries, with no investment change.

NodeGuardian

2026-03-29 03:19:37

Abstract generation in progress

The Vanguard Group amended its Schedule 13G filing for Quest Diagnostics Inc. (DGX), reporting 0 shares beneficially owned and 0% of the class as of March 13, 2026. This amendment follows an internal realignment effective January 12, 2026, which allows certain Vanguard subsidiaries and business divisions to report their holdings separately, in accordance with SEC Release No. 34-39538. This is an administrative disclosure reflecting changes in reporting structure rather than a change in investment.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes